See more : SCVX Corp. (SCVX-UN) Income Statement Analysis – Financial Results
Complete financial analysis of PT Indofarma Tbk (INAF.JK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PT Indofarma Tbk, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Naspers Limited (NPN.JO) Income Statement Analysis – Financial Results
- FE Battery Metals Corp. (FEMFD) Income Statement Analysis – Financial Results
- Great China Metal Ind. Co., Ltd. (9905.TW) Income Statement Analysis – Financial Results
- PT Guna Timur Raya Tbk (TRUK.JK) Income Statement Analysis – Financial Results
- PT Jobubu Jarum Minahasa TBK (BEER.JK) Income Statement Analysis – Financial Results
PT Indofarma Tbk (INAF.JK)
About PT Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company trades in and distributes drugs, medical devices, medical supplies, extracts, and herbals; and operates laboratory. It also provides COVID-19 test services, including rapid diagnostic test antigen; reverse transcription polymerase chain reaction, and genose. The company also exports its products. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is headquartered in Bekasi, Indonesia. PT Indofarma Tbk operates as a subsidiary of PT. Bio Farma.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 523.60B | 1,144.11B | 2,901.99B | 1,715.59B | 1,359.18B | 1,592.98B | 1,631.32B | 1,674.70B | 1,621.90B | 1,381.44B | 1,337.50B | 1,156.05B | 1,203.47B | 1,047.92B | 1,125.06B | 1,478.59B | 1,273.16B | 1,026.68B | 684.04B |
| Cost of Revenue | 695.56B | 1,254.22B | 2,450.33B | 1,314.99B | 1,108.82B | 1,308.76B | 1,348.50B | 1,337.79B | 1,291.84B | 1,069.01B | 999.93B | 788.15B | 807.28B | 729.45B | 820.42B | 1,145.18B | 983.21B | 770.72B | 484.77B |
| Gross Profit | -171.96B | -110.11B | 451.65B | 400.60B | 250.36B | 284.22B | 282.81B | 336.91B | 330.05B | 312.43B | 337.57B | 367.90B | 396.18B | 318.46B | 304.64B | 333.40B | 289.95B | 255.96B | 199.27B |
| Gross Profit Ratio | -32.84% | -9.62% | 15.56% | 23.35% | 18.42% | 17.84% | 17.34% | 20.12% | 20.35% | 22.62% | 25.24% | 31.82% | 32.92% | 30.39% | 27.08% | 22.55% | 22.77% | 24.93% | 29.13% |
| Research & Development | 592.43M | 552.77M | 763.95M | 501.24M | 306.17M | 326.87M | 2.42B | 3.19B | 3.64B | 1.03B | 1.59B | 1.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 115.82B | 42.94B | 45.75B | 41.16B | 31.80B | 30.90B | 28.77B | 35.36B | 28.76B | 31.95B | 57.82B | 40.89B | 110.64B | 92.08B | 83.15B | 80.03B | 77.49B | 66.21B | 57.57B |
| Selling & Marketing | 98.69B | 48.52B | 43.73B | 44.96B | 36.44B | 50.49B | 68.03B | 87.08B | 93.26B | 95.84B | 106.68B | 87.04B | 193.58B | 169.93B | 175.58B | 190.36B | 167.76B | 127.51B | 106.63B |
| SG&A | 216.13B | 91.46B | 89.48B | 86.12B | 68.24B | 81.38B | 96.79B | 122.44B | 122.02B | 127.80B | 164.50B | 127.94B | 304.23B | 262.02B | 258.73B | 270.38B | 245.24B | 193.72B | 164.19B |
| Other Expenses | 222.46B | 246.79B | 305.40B | 212.23B | 172.38B | -7.24B | -1.98B | -602.32M | 1.56B | 3.43B | -3.44B | 1.45B | -3.88B | -9.09B | 565.63M | -8.94B | -8.64B | -6.97B | 202.86M |
| Operating Expenses | 439.18B | 338.25B | 394.89B | 298.35B | 240.62B | 303.58B | 281.95B | 299.68B | 271.73B | 271.75B | 354.00B | 284.39B | 304.23B | 262.02B | 258.73B | 270.38B | 245.24B | 193.72B | 164.19B |
| Cost & Expenses | 1,127.06B | 1,592.47B | 2,845.22B | 1,613.34B | 1,349.44B | 1,612.34B | 1,630.46B | 1,637.47B | 1,563.57B | 1,340.76B | 1,353.93B | 1,072.54B | 1,111.51B | 991.47B | 1,079.15B | 1,415.57B | 1,228.45B | 964.44B | 648.96B |
| Interest Income | 5.56B | 4.54B | 1.84B | 1.10B | 393.10M | 287.79M | 401.74M | 699.77M | 257.07M | 493.64M | 762.46M | 531.16M | 1.21B | 1.05B | 2.24B | 1.37B | 819.28M | 26.53M | 24.92M |
| Interest Expense | 60.49B | 38.08B | 42.96B | 38.25B | 36.76B | 48.17B | 51.33B | 47.26B | 36.90B | 35.30B | 22.09B | 17.00B | 18.15B | 22.35B | 35.34B | 30.27B | 16.12B | 16.44B | 15.58B |
| Depreciation & Amortization | 27.64B | 32.12B | 34.60B | 28.27B | 20.43B | 33.00B | 34.80B | 21.87B | 2.97B | 5.98B | 2.90B | 4.27B | 12.04B | 3.28B | 5.53B | -23.70B | -6.56B | -3.05B | -2.16B |
| EBITDA | -581.38B | -479.11B | 86.68B | 86.76B | 70.76B | 55.87B | 30.51B | 55.38B | 62.54B | 49.05B | -20.62B | 85.84B | 87.24B | 56.45B | 45.91B | 40.14B | 38.19B | 59.19B | 32.92B |
| EBITDA Ratio | -111.04% | -38.51% | 2.46% | 5.93% | 1.82% | -0.60% | 1.36% | 2.65% | 3.86% | 3.71% | -2.98% | 7.37% | 8.64% | 5.70% | 4.57% | 2.66% | 3.00% | 5.76% | 4.81% |
| Operating Income | -603.46B | -479.54B | 51.98B | 87.66B | 16.94B | 25.91B | 2.46B | 37.23B | 58.33B | 40.68B | -16.43B | 78.44B | 91.96B | 56.45B | 45.91B | 63.02B | 44.71B | 62.23B | 35.08B |
| Operating Income Ratio | -115.25% | -41.91% | 1.79% | 5.11% | 1.25% | 1.63% | 0.15% | 2.22% | 3.60% | 2.94% | -1.23% | 6.79% | 7.64% | 5.39% | 4.08% | 4.26% | 3.51% | 6.06% | 5.13% |
| Total Other Income/Expenses | -66.05B | -200.59B | -43.21B | -40.09B | -40.31B | -51.21B | -52.53B | -56.15B | -37.23B | -33.28B | -46.60B | -16.71B | -24.17B | -36.04B | -33.24B | -53.15B | -22.64B | -22.17B | -19.04B |
| Income Before Tax | -669.51B | -517.56B | 8.77B | 18.08B | 9.75B | -25.30B | -56.82B | -18.92B | 14.18B | 7.40B | -63.03B | 61.73B | 55.20B | 20.41B | 12.67B | 9.87B | 22.07B | 40.06B | 16.04B |
| Income Before Tax Ratio | -127.87% | -45.24% | 0.30% | 1.05% | 0.72% | -1.59% | -3.48% | -1.13% | 0.87% | 0.54% | -4.71% | 5.34% | 4.59% | 1.95% | 1.13% | 0.67% | 1.73% | 3.90% | 2.34% |
| Income Tax Expense | 51.49B | -89.07B | 46.34B | 18.05B | 1.78B | 7.44B | -10.53B | -1.55B | 7.61B | 6.24B | -8.81B | 19.35B | 18.28B | 7.86B | 10.54B | 4.83B | 11.00B | 24.82B | 6.44B |
| Net Income | -720.99B | -428.49B | -37.57B | 27.58M | 7.96B | -32.74B | -46.28B | -17.37B | 6.57B | 1.17B | -54.22B | 42.38B | 36.92B | 12.55B | 2.13B | 5.03B | 11.08B | 15.24B | 9.59B |
| Net Income Ratio | -137.70% | -37.45% | -1.29% | 0.00% | 0.59% | -2.06% | -2.84% | -1.04% | 0.40% | 0.08% | -4.05% | 3.67% | 3.07% | 1.20% | 0.19% | 0.34% | 0.87% | 1.48% | 1.40% |
| EPS | -232.63 | -138.25 | -12.12 | 0.01 | 2.57 | -10.56 | -14.93 | -5.60 | 2.12 | 2.02 | -17.50 | 13.68 | 11.93 | 4.05 | 0.69 | 0.02 | 3.57 | 4.92 | 3.10 |
| EPS Diluted | -232.63 | -138.25 | -12.12 | 0.01 | 2.57 | -10.56 | -14.93 | -5.60 | 2.12 | 2.02 | -17.50 | 13.68 | 11.93 | 4.05 | 0.69 | 0.02 | 3.57 | 4.92 | 3.10 |
| Weighted Avg Shares Out | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.07B | 3.10B | 3.10B | 3.09B | 3.10B | 3.08B | 3.10B | 3.10B | 3.10B | 3.10B |
| Weighted Avg Shares Out (Dil) | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.10B | 3.09B | 3.10B | 3.08B | 3.10B | 3.10B | 3.10B | 3.10B |
No news found for: INAF.JK
Source: https://incomestatements.info
Category: Stock Reports